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Jeffrey M. Burns, MD, MS; David K. Johnson, PhD; Amber Watts, PhD;
Russell H. Swerdlow, MD; William M. Brooks, PhD
Objective: To examine body composition in individu-
als with early AD and without dementia and its relation
to cognition and brain volume.
Design: Cross-sectional case-control study.
Participants: Individuals without dementia (Clinical De-
mentia Rating, 0; n=70) and with early-stage AD (Clini-
cal Dementia Rating, 0.5 or 1; n=70) in the Alzheimer
and Memory Program at the University of Kansas School
of Medicine.
Main Outcome Measures: Participants were evalu-
ated with brain magnetic resonance imaging (MRI), neu-
ropsychological testing, and dual-energy x-ray absorp-
tiometry to determine whole-body fat and lean masses.
Body mass index was calculated as weight in kilograms
divided by height in meters squared.
Results: Lean mass was reduced in persons with early
AD compared with controls without dementia (F=7.73;
P=.006) after controlling for sex. Whole-brain volume
(=.20; P .001), white matter volume (=.19; P .001),
and global cognitive performance (=.12; P=.007) were
associated with lean mass (dependent variable) when con-
trolling for age and sex. The total body fat and percent-
age of body fat values were not different across groups
or related to cognition and brain volume.
Conclusion: Loss of lean mass is accelerated in AD and
is associated with brain atrophy and cognitive perfor-
mance, perhaps as a direct or indirect consequence of AD
pathophysiology or through shared mechanisms com-
mon to both AD and sarcopenia.
Arch Neurol. 2010;67(4):428-433
A LZHEIMER DISEASE (AD) ISassociated with unin-tended weight loss1 thatbegins years prior to therecognition of AD-related
clinical symptoms2-4 and may be a marker
of preclinical AD.5 Weight loss in AD is
associated with dementia severity and
faster clinical progression.1 Epidemiologi-
cal studies suggest a complex relation-
ship between body composition and de-
mentia that may be variable across the age
spectrum. Although obesity in midlife is
a risk factor for developing dementia,6,7
overweight and obesity in late life are as-
sociated with lower dementia risk.8,9 Most
studies of body composition in dementia
and AD are limited by nonspecific mea-
sures of body composition such as total
body weight or body mass index (BMI; cal-
culated as weight in kilograms divided by
height in meters squared) rather than spe-
cific measures of body fat and muscle mass.
As normal aging is associated with in-
creases in body fat and declines in lean
mass without overall weight loss, nonspe-
cific adiposity measures such as BMI have
limited value in capturing these changes.
We used dual-energy x-ray absorpti-
ometry (DEXA) to quantify body compo-
sition in subjects with early-stage AD and
without dementia. We examined whether
alterations in specific components of body
composition (ie, lean mass vs fat mass)
were apparent in individuals in the earli-
est clinical stages of AD. Given previous
studies relating body composition to AD
severity and progression, we also exam-
ined the relationship of body compo-
sition to cognition. Additionally, AD-
related brain changes including medial
temporal lobe atrophy10 and neuropatho-
logical burden (plaques and tangles)11 are
associated with reduced BMI, suggesting
that neurodegenerative processes may con-
tribute to alterations in body composi-
tion. Thus, we further examined the
relationship of components of body com-
position to imaging measures of neurode-
generation (ie, brain atrophy). Because
weight loss is associated with AD progres-
sion and altered body composition, we hy-
pothesized that body composition would be
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METHODS
SAMPLE AND RECRUITMENT
Participants were aged 60 years and older and either did not have
dementia (Clinical Dementia Rating [CDR], 0; n=70) or were
diagnosed with early-stage AD (CDR, 0.5; n=56 and CDR, 1;
n=14) as detailed below. Participants without dementia and 63%
of the participants with AD were self-referred from the commu-
nity (primarily through media coverage and word of mouth),
while 37% of the participants with AD were recruited from a re-
ferral-based memory clinic. Study exclusions included neuro-
logic disease other than AD, diabetes mellitus, recent (2 years)
history of ischemic heart disease, clinically significant depres-
sive symptoms, use of antipsychotic and investigational medi-
cations, and significant sensory impairment or systemic illness
that could impair completion of the study. All participants were
required to be accompanied by a study partner who was knowl-
edgeable about the participant’s daily activities. We have previ-
ously reported results from subsamples of this cohort.12-14
CLINICAL ASSESSMENT
All participants were evaluated using a semistructured inter-
view of the participant and a study partner to determine the pres-
ence or absence of dementia and its severity, if present, using
the CDR.15 Diagnostic criteria for AD require the gradual onset
and progression of impairment in memory and at least 1 other
cognitive and functional domain.16 These diagnostic methods have
an accuracy of 93% for AD17 and sensitively detect the earliest
stages of AD by focusing on intraindividual change rather than
comparison with group reference values.18 Additionally, they ac-
curately identify the subset of individuals who meet criteria for
mild cognitive impairment and have early-stage AD.19 A global
CDR score is derived from individual ratings in each domain,
with a CDR of 0 indicating no dementia; 0.5, very mild demen-
tia; and 1, mild dementia. Subjects with moderate (CDR, 2) or
severe (CDR, 3) dementia were not enrolled in the study.
A nurse clinician collected medication information, medi-
cal history, education, and demographics from the study part-
ner. A neurologist performed a standard physical and neuro-
logical examination. Functional activity level was estimated using
the Mild Cognitive Impairment Activities of Daily Living Scale.20
The Geriatric Depression Scale21 was given to the collateral source
for all participants and used as a continuous variable for analy-
sis. Apolipoprotein E genotyping was conducted using restric-
tion enzyme isotyping.22
NEUROPSYCHOLOGICAL ASSESSMENT
A trained psychometrician gave a standardized psychometric
battery of tests to all participants, as previously described.12-14
The battery included the standard measures of Logical Memory
I and II, Free and Cued Selective Reminding Task, Boston Nam-
ing Test-15 item, Verbal Fluency, Digit Span Forward and Back-
ward, Letter-number sequencing, Trail making A and B, Stroop
Color-Word Test, and Block Design. Cognitive performance
scores were converted to z scores based on the mean and stan-
dard deviations of subjects without dementia. The means of each
participant’s z scores served as an index of global cognitive per-
formance. The Mini-Mental State Examination (MMSE) was also
given as a measure of global cognition.
BODY COMPOSITION
Dual-energy x-ray absorptiometry (GE Lunar Corp, Madison,
Wisconsin) was used to determine total body measures of lean
and fat mass. Percentage of body fat represents the percentage
of total body mass (determined by DEXA) composed of fat (ie,
total fat  100/total body mass). We used total body mass de-
termined by DEXA. Mass determined by DEXA was highly cor-
related with our manually measured (by scale) body weight
(r=0.99; P .001) and also minimized the influence of cloth-
ing. Height was measured using a standard stadiometer.
OTHER CLINICAL MEASURES
We also examined potential covariates that may mediate brain
and body composition relationships including habitual level of
physical activity, frailty, and laboratory assessments of insu-
lin, lipids, inflammation, and apolipoprotein E4 allele status,
as previously described.12-14 Briefly, level of habitual physical
activity was estimated using the Physical Activity Scale in the
Elderly, a reliable and valid measure of physical activity devel-
oped specifically for older individuals.23 The Physical Activity
Scale in the Elderly estimates an individual’s level of physical
activity in the last 7 days by assessing the frequency and du-
ration of participation in a variety of activities. The Physical
Activity Scale in the Elderly was given to both the subject and
the study partner and, for individuals with AD, data collected
from the study partner were used in the analyses. We assessed
peripheral insulin levels by radioimmunoassay using a fast-
ing, 14-sample, 3-hour intravenous glucose tolerance test as
previously described.13 Total 3-hour area under the curve (AUC)
values for glucose and insulin served as overall indices of glu-
cose and insulin levels. The Physical Performance Test was used
as a measure of physical performance and frailty.24 Fasting ve-
nous blood samples were assessed using commercial enzy-
matic assays for total cholesterol (Diagnostic Chemicals, Ltd,
Oxford, Connecticut). Highly sensitive C-reactive protein was
determined in fasting blood by turbidimetric assay (Roche Di-
agnostics Systems, Basel, Switzerland).
NEUROIMAGING
Structural magnetic resonance imaging was obtained for all par-
ticipants using a Siemens 3.0 Tesla Allegra MRI scanner
(Siemens Medical Solutions, Erlangen, Germany). High-
resolution T1-weighted anatomic images were acquired to pro-
vide detailed gross anatomy with high gray/white matter con-
trast (magnetization-prepared 180° radiofrequency pulses and
rapid gradient-echo; 1  1  1 mm3 voxels; time to repeti-
tion,2500 milliseconds; echo time,4.38 milliseconds; time fol-
lowing inversion pulse,1100 milliseconds; field of view, 256
 256 mm2 with 18% oversample; flip angle,8 degrees). Nor-
malized whole-brain volume (WBV) was computed for each
imaging session using validated imaging tools from the FMRIB
Software Library (http://www.fmrib.ox.ac.uk/fsl), as previ-
ously described,12 using the Laboratory of Neuro Imaging
Pipeline (University of California Los Angeles; http://pipeline
.loni.ucla.edu). Briefly, the images were preprocessed and skull-
stripped using the Brain Extraction Tool. Skull-stripped im-
ages were then segmented into white matter, gray matter, and
cerebrospinal fluid using FMRIB’s Automated Segmentation Tool
by registering them to the Montreal Neuroimaging Institute
avg152 template. Normalized volumes for white matter (WMV),
gray matter (GMV), and the whole brain (WBV; sum of white
and gray matter) were calculated by dividing each by the total
intracranial volume (the sum of white, gray, and cerebrospi-
nal fluid volumes) and expressed as the percentage of the total
intracranial volume. Normalized brain volumes minimize sex
differences and produce an estimate of brain atrophy. Imaging
data was unavailable for 3 participants without dementia and
1 with early AD.
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STATISTICAL ANALYSIS
Analyses were conducted using SPSS 16.0 (SPSS Inc, Chicago,
Illinois). Continuous variables were summarized by means and
standard deviations and categorical variables were summa-
rized by frequency and percentage. The t test was used to com-
pare continuous demographic and imaging variables in groups
with early AD and without dementia. A 2 test was used to com-
pare categorical variables. Pearson correlation coefficients were
calculated to assess simple relationships between variables.
A multistep hierarchical linear regression was conducted to
examine the relationship between clinical predictors (ie, brain
volume, cognition) with body composition (ie, BMI, lean mass,
and fat mass as dependent variables). All analyses controlled
for age and sex. Variables correlating with body composition
(ie, dementia status, physical activity, and insulin [3-hour AUC])
were used as covariates, and the increment in R2 assessed the
additional variance predicted from each new variable entered
into the model. A final exploratory regression model exam-
ined the influence of all variables of interest and covariates on
body composition. Age and sex were forced into the model in
step 1, with covariates later entered in a stepwise fashion.
RESULTS
DESCRIPTIVE STATISTICS
Participant characteristics are summarized in Table 1.
The control and early-AD groups were well matched with
respect to age (mean [SD], 74.1 [6.8] years) and sex (58%
female). Participants with early AD were slightly less edu-
cated than controls (15.2 years vs 16.5 years; t=2.60;
P=.01). As expected, they also demonstrated mild global
cognitive dysfunction. On average, they scored 3.4 points
lower on the MMSE (of 30 points) and 1.7 SD (z scored)
lower on the global cognitive composite index than con-
trols without dementia. More participants with early AD
were carriers of the apolipoprotein E4 allele. The groups
did not differ on clinical indices of metabolic function
(total cholesterol, C-reactive protein, insulin AUC, and
glucose AUC).
Brain volumetrics demonstrated evidence of whole-
brain and gray matter atrophy in early AD, with no dif-
ference in WMV across groups, suggesting that differ-
ences in WBV were driven by reduced GMV in the
participants with AD.
Indices of physical function were significantly lower in
early AD. Individuals with early AD had impairments in
activities of daily living (Mild Cognitive Impairment Ac-
tivities of Daily Living Scale) and physical function (Physi-
cal Performance Test) and lower levels of habitual physi-
cal activity (Physical Activity Scale in the Elderly).
BODY COMPOSITION IN PARTICIPANTS
WITH AD AND WITHOUT DEMENTIA
Body mass index, body weight, and body fat measures
were not different across the control and early-AD groups
(Table 2). Total lean mass was reduced in individuals
with early AD compared with controls after controlling
for known sex differences in lean mass (F=7.73; P=.006).
There were no dementia group  sex interactions, sug-
gesting that AD-related differences in lean mass were not
different in men and women.
To identify potential mediators of reduced lean mass
in AD, we performed a series of linear regressions that
examined the relationship of individual covariates with
lean mass (dependent variable). Because age and sex in-
fluence lean mass and all of the clinical covariates tested
(all .10; P.01), we included age and sex as the first
step in all regression analyses and report resultant par-
tial correlations as standardized  values (Table 3).
The strongest predictor of lean mass was WBV
(Figure), largely driven by a relationship between WMV
and lean mass. Gray-matter volume was not related to
lean mass. Additional significant correlates related to lean
mass included cognitive indices (global cognitive per-
formance and MMSE), insulin levels (3-hour AUC), and
habitual physical activity levels. Glucose, C-reactive pro-









Age, y 73.3 (7.3) 74.9 (6.7) .17
Education, y 16.5 (2.7) 15.2 (3.3) .01
Sex, male/female 30/40 29/41 .86
Apolipoprotein E4 carrier,
No. (%)
19 (27.9) 59.1 (39) .001
Mini-Mental State Examination
score
29.4 (0.8) 26.0 (3.5) .001
Global cognitive performance,
z score
0.0 (1.0) −1.7 (1.8) .001
Whole-brain volume, % ICV 78.0 (2.9) 75.3 (3.3) .001
White matter volume, % ICV 35.0 (1.9) 34.6 (2.4) .32
Gray matter volume, % ICV 43.0 (2.5) 40.6 (2.4) .001
Activities of daily living 48.5 (3.3) 40.2 (7.8) .001
Physical performance test 30.5 (3.4) 27.6 (3.9) .001
Physical activity level,
PASE score
130.4 (51.8) 88.9 (56.7) .001
Total cholesterol, mg/dL 182.6 (34.0) 188.1 (37.4) .37
C-reactive protein, mg/L 2.3 (2.4) 1.8 (1.5) .11
Insulin area under the curvea 2540 (1361) 2903 (1747) .18
Glucose area under the curvea 22 475 (2851) 23 049 (4541) .38
Abbreviations: AD, Alzheimer disease; % ICV, percentage of intracranial
volume; PASE, Physical Activity Scale in the Elderly.
SI conversion factors: to convert total cholesterol to millimoles per liter,
multiply by 0.0259; C-reactive Protein to nanomoles per liter, 9.524.
aArea under the curve generated from a 3-hour intravenous glucose
tolerance test.
Table 2. Body Composition in Participants
With Early AD and Controls
Variable
Mean (SD)
Control Early AD P Valuea
Body mass indexb 25.7 (3.6) 25.0 (3.9) .38
Weight, kg 73.2 (14.0) 69.1 (12.9) .10
Height, cm 169.6 (11.2) 166.2 (9.1) .14
Fat mass, kg 25.8 (8.3) 24.7 (8.7) .41
Body fat, % 35.3 (8.7) 35.4 (9.7) .93
Lean mass, kg 44.6 (10.4) 41.9 (9.3) .02
aGroup comparison by general linear model, controlling for age and sex.
bCalculated as weight in kilograms divided by height in meters squared.
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tein, activities of daily living, physical performance, de-
pressive symptoms, and apolipoprotein E4 status were
not related to lean mass. Thus, additional analyses in-
cluded further examination of the clinical and func-
tional significance of body composition in AD in rela-
tion to brain volume, cognition, and the covariates of




formance and MMSE) were related to lean mass (Table 3).
Cognitive performance was not related to other measures
of body composition (BMI, total body fat, and percentage
of body fat). As our global cognitive performance measure
is a composite measure of a variety of cognitive tests, we
nextassessedtherelationshipof leanmasswithperformance
on component cognitive subtests. Lean mass was associ-
ated with performance on the Logical Memory I (=.12;
P=.007), Logical Memory II (=.09; P=.04), Trail Making
A (=−.09; P=.05), Trail Making B (=−.11; P=.01), Cat-
egory Fluency (=.09; P=.05), Block Design (=.13;
P=.005),andDigitSpanForward(=.10;P=.03)tests.There
were no dementia status  cognitive performance interac-
tions in predicting lean mass, suggesting that the relation-
ship between lean mass and cognition is similar in partici-
pantswithADandthosewithoutdementia.Controlling for
dementia status, however, resulted in attenuation of these
results, suggesting thatgroupdifferences inbothcognition
and lean mass may be responsible for the results.
BODY COMPOSITION
AND BRAIN STRUCTURE
Regression analyses identified a relationship between WBV
and lean mass (Figure). This relationship was driven pri-
marily by a relationship between WMV and lean mass
(=.19; P .001). In contrast, GMV was unrelated to lean
mass. The association of WBV and WMV with lean mass
was unchanged after controlling for additional covariates
of dementia status, physical activity, global cognition, and
insulin AUC. There were no dementia status  WBV or
sex  WBV interactions, suggesting that the positive re-
lationship between WBV and body composition was simi-
lar in participants with AD vs controls and men vs women.
Whole-brain volume was not related to total body fat
(=.14; P=.21) or percentage of body fat (=.01; P=.89)
but was modestly associated with BMI (=.20; P=.05),
with higher BMI associated with higher brain volume (ie,
less brain atrophy). Although BMI is a proxy measure for
adiposity (r=0.55; P .001), it also reflects lean mass
(r=0.28; P=.001), and thus the modest relationship be-
tween BMI and WBV appears to be largely driven by the
observed lean mass–WBV relationship.
OVERALL MODEL
We next examined an overall model that included all vari-
ables of interest (WBV, global cognition) and covariates
(age, sex, dementia status, physical activity, and insulin
levels) to assess which variables were most strongly re-
lated to lean mass. Age, sex, and dementia status (AD vs
control) were forced into the model (step 1), with all co-
variates assessed in step 2 using a stepwise model of in-
clusion (F=3.94; P .05 to retain). In this model, WBV
(=.12; P=.04), insulin (3-hour AUC; =.10; P=.02),
and physical activity level (=.11; P=.02) were each in-
dependently associated with lean mass. When WMV and
GMV were used rather than WBV, WMV, but not GMV,
was retained (= .17; P .001) with insulin (= .09;
P=.05) and physical activity (=.12; P=.009).
COMMENT
Our findings are consistent with prior studies indicat-
ing that alterations in body composition are apparent in
Table 3. Standardized Coefficients () Predicting Lean Mass
After Controlling for Age and Sexa
Variable  P Value
Whole-brain volume, normalized .20 .001
Gray matter volume, normalized .06 .27
White matter volume, normalized .19 .001
Global cognitive performance .12 .007
Mini-Mental State Examination .11 .009
Insulin, AUC .11 .02
Glucose, AUC .09 .05
C-reactive protein .003 .94
Physical activity (PASE) .14 .001
Activities of daily living .07 .09
Physical performance task .07 .16
Depression −.05 .21
Apolipoprotein E4 carrier −.05 .24
Abbreviations: AUC, area under the curve; PASE, Physical Activity Scale in
the Elderly.
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Figure. Relationship between lean mass and whole-brain volume.
Whole-brain volume is positively associated (=.20; P .001) with lean
mass in participants with early Alzheimer disease (AD) and controls without
dementia. Whole-brain volume is normalized to account for differences in
head size and provide an estimate of brain atrophy. For illustrative purposes
in the figure, lean mass was adjusted for sex and age and presented in
standardized units [Z]. This positive association was not different across the
Alzheimer disease and control groups and was independent of age, sex,
dementia severity, inflammation, insulin, and glucose measures.
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the earliest clinical stages of AD2-4 and extends these find-
ings by suggesting that AD-related alterations in body
composition may be predominantly related to loss of lean
mass (ie, sarcopenia). This is consistent with at least one
large epidemiological study that found an association be-
tween cognitive impairment and reduced muscle mass
in women without dementia.25 Although the cross-
sectional, case-control study design limits our ability to
infer causal relationships, our data suggest that sarcope-
nia may be accelerated in the earliest stages of AD.
Our findings also suggest that lean mass may be a more
sensitive measure to relate body composition to cogni-
tive outcomes and dementia than measures of adipos-
ity. Lean mass was reduced in individuals with AD com-
pared with controls and was associated with brain volume
and cognition; total body fat, however, was not related
to dementia status, brain volume, or cognition. Al-
though we observed a modest relationship between the
nonspecific adiposity measure BMI and brain volume, this
relationship was primarily driven by lean mass, as only
lean mass, and not fat mass, was associated with WBV.
Thus, our data highlight the importance of assessing spe-
cific measures of body composition and suggest the hy-
pothesis that loss of lean mass may underlie previously
described relationships of nonspecific measures of body
composition (ie, BMI) with cognitive decline and de-
mentia.9,26,27
We observed a direct correlation between WBV (an
estimate of brain atrophy) and lean mass, suggesting that
brain atrophy and loss of muscle mass may co-occur. Brain
atrophy is considered a neuroimaging measure reflec-
tive of AD pathology.28 Thus, our data are consistent with
other studies suggesting that brain pathology may con-
tribute to decline in body composition,11 perhaps by dis-
rupting central nervous system regulation of energy
metabolism and food intake.29 While AD and neurode-
generation predominantly affect gray matter, we find it
particularly interesting that we observed a strong rela-
tionship between lean mass and WMV rather than GMV,
and this relationship was similar in participants without
dementia and those with AD, suggesting that mecha-
nisms other than AD processes may underlie these rela-
tionships.
Sarcopenia in normal aging is most strongly associ-
ated with age-related reductions in physical activity.30 In
our cohort, individuals with early AD had reduced physi-
cal activity levels compared with the cohort without de-
mentia. Additionally, lower physical activity was asso-
ciated with less lean mass, suggesting that behavioral
changes associated with AD may result in loss of lean mass.
Alternatively, physical activity itself may attenuate the
structural and functional brain and body changes asso-
ciated with AD and aging. This is biologically plausible
given accumulating animal and human evidence link-
ing exercise and physical fitness with brain health.12,31-33
Even after controlling for physical activity levels, how-
ever, lean mass remained independently associated with
brain volume, suggesting that the decline in physical ac-
tivity observed in aging and AD is unlikely to fully ex-
plain our results.
An alternative explanation for our observations is that
AD and sarcopenia share common underlying mecha-
nisms. Alzheimer disease is associated with systemic ana-
bolic and inflammatory abnormalities that are also im-
plicated in sarcopenia.34-37 Although our measures of
anabolic and inflammatory processes are limited in this
study, we observed an independent relationship be-
tween lean mass and insulin, a well-known anabolic hor-
mone38 that may have neurotrophic39 and neuroprotec-
tive40 properties. We previously reported that insulin levels
are associated with cognition and brain volume in early
AD and, as in this study, the association was stronger for
white matter than gray.13 Interestingly, insulin signal-
ing preferentially affects the development of white mat-
ter structures,41 which, taken with our prior results, sug-
gests that insulin signaling may play a role in maintaining
cerebral white matter. Thus, our observation that WMV,
lean mass, and insulin levels are interrelated suggests that
reduced anabolic support to both the muscle and brain
may be a potential mechanism underlying the observed
relationships.
The current study is limited by its cross-sectional de-
sign, and further longitudinal and interventional stud-
ies will be necessary to more precisely define the nature
and mechanisms of body composition changes in AD. Al-
though clinical methods are imperfect in predicting AD
pathology, we used sensitive18 and validated17 methods
for diagnosing the earliest stages of AD. Additionally, par-
ticipants were a convenience sample, which limits gen-
eralizability and may have introduced sampling bias that
could affect the results. The relatively small sample size
(n=140) could limit the power to resolve group differ-
ences or important interactions for marginal effects and
thus increase the chance of type II error. Additionally,
potentially important dietary factors were not mea-
sured. Nevertheless, our data suggest that loss of lean mass
may be accelerated in AD, perhaps as a direct or indirect
consequence of AD pathophysiology or through shared
mechanisms common to both AD and sarcopenia.
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